R
R.M. Glasspool
Researcher at Beatson West of Scotland Cancer Centre
Publications - 15
Citations - 1115
R.M. Glasspool is an academic researcher from Beatson West of Scotland Cancer Centre. The author has contributed to research in topics: Cancer & Bevacizumab. The author has an hindex of 9, co-authored 15 publications receiving 614 citations.
Papers
More filters
Journal ArticleDOI
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo,Cristiana Sessa,A. du Bois,Jonathan A. Ledermann,WG McCluggage,Iain A. McNeish,P. Morice,Sandro Pignata,Isabelle Ray-Coquard,Ignace Vergote,Thaïs Baert,I. Belaroussi,A. Dashora,Siel Olbrecht,François Planchamp,Denis Querleu,Susana Banerjee,P. Blecharz,Ilan Bruchim,David Cibula,Nicole Concin,Ben Davidson,Mojgan Devouassoux-Shisheboran,Annamaria Ferrero,R.M. Glasspool,Antonio González-Martín,Viola Heinzelmann-Schwarz,Florence Joly,J. W. Kim,Frédéric Kridelka,Domenica Lorusso,Sven Mahner,Mikio Mikami,Mansoor Raza Mirza,Shibani Nicum,Dearbhaile M. O'Donnell,Patricia Pautier,Alexandros Rodolakis,Jalid Sehouli,Fatih Selcukbiricik,Naveena Singh,David S.P. Tan,Dirk Timmerman,Germana Tognon,J. van der Velden,Petronella O. Witteveen,AG Zeimet +46 more
TL;DR: The recommendations presented here are based on the best available evidence and expert agreement and are presented with a summary of evidence supporting each recommendation.
Journal ArticleDOI
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Yvette Drew,Jonathan A. Ledermann,Geoff Hall,Daniel Rea,R.M. Glasspool,Martin Highley,Gordon C Jayson,Julieann Sludden,James W. Murray,David Jamieson,Sarah Halford,Gary Acton,Zoe Backholer,Raffaella Mangano,Alan V. Boddy,Nicola J. Curtin,Ruth Plummer +16 more
TL;DR: In this article, intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer were investigated.
Journal ArticleDOI
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer,Catherine M Shannon,Klaus Baumann,Joern Rau,Philipp Harter,Florence Joly,Jalid Sehouli,Ulrich Canzler,Barbara Schmalfeldt,Barbara Schmalfeldt,Andrew Dean,Alexander Hein,Alain G. Zeimet,Lars Hanker,Thierry Petit,Frederik Marmé,Ahmed El-Balat,Rosalind Glasspool,Nikolaus de Gregorio,Sven Mahner,Sven Mahner,Tarek M Meniawy,Tjoung-Won Park-Simon,Marie-Ange Mouret-Reynier,Cristina Costan,Werner Meier,Alexander Reinthaller,Jeffrey C Goh,Tifenn Lharidon,Sally Baron Hay,Stefan Kommoss,Andreas du Bois,Jean-Emmanuel Kurtz,Sven Ackermann,Christoph Anthuber,Mustafa Aydogdu,Angelika Baldauf,Wolfgang Bauer,Dirk Behringer,Antje Belau,Alexandra Bender,C Brucker,Alexander Burges,Trygve Daabach,Dominik Denschlag,Mustafa Deryal,Steffen Dörfel,Juliane Ebert,Tanja Fehm,Susanne Maria Feidicker,Gabriele Feisel-Schwickardi,Ricardo Felberbaum,Matthias Frank,Gerhard Gebauer,Bernd Gerber,Axel Gerhardt,Andrea Grafe,Martin Griesshammer,Eva-Maria Grischke,Isolde Gröll,Martina Gropp-Meier,Dietrich Hager,Volker Hanf,Carla Verena Hannig,Peer Hantschmann,Tanja Hauzenberger,Uwe Herwig,Martin Heubner,Carsten Hielscher,Felix Hilpert,Thomas Hitschold,Manfred Hofmann,Christian Jackisch,Wolfgang Janni,Ludwig Kiesel,Yon-Dschun Ko,Hans-Joachim Koch,Petra Krabisch,Peter Krieger,Thomas Kubin,Thorsten Kühn,Björn Lampe,Peter Ledwon,Sabine Lemster,Benno Lex,Clemens Liebrich,Ralf Lorenz,Hans-Joachim Lück,Peter Mallmann,Wolfgang Meinerz,Götz Menke,Volker Möbus,Thomas G. Müller,Volker Müller,Tanja Neunhöffer,Angelika Ober,G. Oskay-Özcelik,Horst Ostertag,Martin Pölcher,Beate Rautenberg,Daniel Rein,Wilhelm Reiter,Andreas Rempen,Ingo B. Runnebaum,Marcus Schmidt,Sabine Schnohr,Heinz Scholz,Willibald Schröder,Eike Simon,Antje Sperfeld,Annette Steckkönig,Hans-Georg Strauß,Ronaldo Stuth,Jürgen Terhaag,Falk Thiel,Marc Thill,Oliver Tomé,Christoph Uleer,Susanne Vogel,Hermann Voß,Michael Weigel,Ulrich Winkler,Arthur Wischnik,Tobias Zeiser,Andreas Zorr,R.M. Glasspool,Emma Hudson,Rachel Jones,Judith Lafleur,Christian Marth,Edgar Petru,Yoland Antill,Mary Azer,Sally Baron-Hay,Philip Beale,Stephen Begbie,Allison Black,Karen Briscoe,Andrew Dean,Jeffrey C. Goh,Sandra Harvey,Chee Lee,Marco Matos,Tarek Meniawy,Inger Olesen,Catherine Shannon,Paul A. Vasey,Sophie Abadie-Lacourtoisie,Olivier Arsene,Sophie Barthier,Célia Becuwe-Roemer,Dominique Berton-Rigaud,Maria Cappiello-Bataller,Stéphanie Catala,Francesco Del Piano,Gael Deplanque,Raymond Despax,Nadine Dohollou,Claire Garnier-Tixidré,Julien Grenier,Emmanuel Guardiola,Anne-Claire Hardy-Bessard,Claudia Lefeuvre-Plesse,Marianne Leheurteur,Anne Lesoin,Charles-Briac Levache,Raffaele Longo,Alain Lortholary,Jérôme Meunier,Nadia Raban,Olivier Romano,Jean-Michel Vannetzel,Alain Zannetti +172 more
TL;DR: This multicentre, open-label, randomised, phase 3 trial was to compare a standard bevacizumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacsumab for progression-free survival in recurrent ovarian cancer.
Journal ArticleDOI
Prognostic gene expression signature for high-grade serous ovarian cancer.
Joshua Millstein,Timothy Budden,Timothy Budden,Ellen L. Goode,Michael S. Anglesio,Aline Talhouk,Maria P. Intermaggio,H.S. Leong,S. Chen,Wafaa Elatre,Blake Gilks,Tayyebeh M. Nazeran,Mila Volchek,Rex C. Bentley,Chen Wang,D.S. Chiu,Stefan Kommoss,S.C.Y. Leung,Janine Senz,Amy Lum,V. Chow,Hanwei Sudderuddin,Robertson Mackenzie,Joshy George,David D.L. Bowtell,Georgia Chenevix-Trench,A. Green,P. Webb,Anna deFazio,D. Gertig,Nadia Traficante,Sian Fereday,S. Moore,J. Hung,K. Harrap,T. Sadkowsky,N. Pandeya,M. Malt,A. Mellon,R. Robertson,T. Vanden Bergh,M. Jones,P. Mackenzie,J. Maidens,K. Nattress,Y.E. Chiew,A. Stenlake,H. Sullivan,B. Alexander,P. Ashover,Scott W. Brown,T. Corrish,Lawrence W. Green,L. Jackman,K. Ferguson,K. Martin,A. Martyn,B. Ranieri,J. White,V. Jayde,P. Mamers,L. Bowes,L. Galletta,David H. Giles,Joy Hendley,Kathryn Alsop,Tiffany M. Schmidt,H. Shirley,C. Ball,C. Young,S. Viduka,Hoa Tran,Sanela Bilic,Lydia Glavinas,Julia Brooks,R. Stuart-Harris,F. Kirsten,J. Rutovitz,P. Clingan,Amy E. Glasgow,A. Proietto,S. Braye,Geoffrey Otton,J. Shannon,Tony Bonaventura,J. Stewart,S. Begbie,M. Friedlander,D. Bell,S. Baron-Hay,a A. Ferrier,G. Gard,D. Nevell,Nick Pavlakis,S. Valmadre,B. Young,C. Camaris,R. Crouch,L. Edwards,Neville F. Hacker,D. Marsden,G. Robertson,P. Beale,Jane Beith,J. Carter,C. Dalrymple,R. Houghton,P. Russell,M. Links,J. Grygiel,J. Hill,A. Brand,Karen Byth,R. Jaworski,Paul R. Harnett,Raghwa Sharma,G. Wain,B. Ward,D. Papadimos,A. Crandon,M. Cummings,Keith Horwood,Andreas Obermair,Lewis Perrin,D. Wyld,J. Nicklin,Margaret Davy,Martin K. Oehler,Chad A. Hall,T. Dodd,T. Healy,K. Pittman,D. Henderson,Judy Miller,J. Pierdes,Penny Blomfield,D. Challis,R. McIntosh,Alan L. Parker,Bruce M. Brown,Robert M. Rome,David W. Allen,Peter Grant,Simon Hyde,R. Laurie,M. Robbie,David L. Healy,Tom Jobling,T. Manolitsas,J. McNealage,Peter Rogers,Beatrice Susil,E. Sumithran,I. Simpson,Kelly-Anne Phillips,Danny Rischin,Stephen B. Fox,Daniel Johnson,Stephen Lade,M. Loughrey,N. O’Callaghan,William K. Murray,Paul Waring,V. Billson,Jan Pyman,Deborah Neesham,Michael C. J. Quinn,C. Underhill,R. Bell,L.F. Ng,R. Blum,Vinod Ganju,Ian Hammond,Y. Leung,Anthony McCartney,Michael D. Buck,Izhak Haviv,David M. Purdie,David C. Whiteman,Nikolajs Zeps,Helen Steed,Jennifer M Koziak,Martin Köbel,Iain A. McNeish,Iain A. McNeish,Teodora Goranova,Darren Ennis,Darren Ennis,Geoff Macintyre,D. Silva De Silva,T. Ramón y Cajal,Jesús García-Donas,S. Hernando Polo,Gustavo C. Rodriguez,Kara L. Cushing-Haugen,Holly R. Harris,Holly R. Harris,Casey S. Greene,Rene A. Zelaya,Sabine Behrens,Renée T. Fortner,Peter Sinn,E. Herpel,E. Herpel,Jenny Lester,Jenny Lester,Jan Lubinski,Oleg Oszurek,A. Toloczko,Cezary Cybulski,Janusz Menkiszak,Celeste Leigh Pearce,Celeste Leigh Pearce,M. C. Pike,M. C. Pike,C. Tseng,Jennifer Alsop,Valerie Rhenius,H. Song,Mercedes Jimenez-Linan,Anna M. Piskorz,A Gentry-Maharaj,Chloe Karpinskyj,Martin Widschwendter,Naveena Singh,Catherine J. Kennedy,Catherine J. Kennedy,P.R. Harnett,P.R. Harnett,Bo Gao,Bo Gao,Sharon E. Johnatty,R. Sayer,J. Boros,J. Boros,Stacey J. Winham,Gary L. Keeney,Scott H. Kaufmann,Melissa C. Larson,H. Luk,Brenda Y. Hernandez,Pamela J. Thompson,L R Wilkens,Michael E. Carney,Britton Trabert,Jolanta Lissowska,L A Brinton,Mark E. Sherman,Clara Bodelon,Samantha Hinsley,Liz-Anne Lewsley,R.M. Glasspool,Susana Banerjee,Euan A. Stronach,Paul Haluska,I.L. Ray-Coquard,Sven Mahner,Boris Winterhoff,DJ Slamon,Douglas A. Levine,Douglas A. Levine,Linda E. Kelemen,Javier Benítez,Jenny Chang-Claude,Jenny Chang-Claude,Jacek Gronwald,A.H. Wu,Usha Menon,M. T. Goodman,Joellen M. Schildkraut,N. Wentzensen,Robert S. Brown,Andrew Berchuck,Simon A. Gayther,María Josefa Mosteiro García,Michelle J. Henderson,Mary Anne Rossing,Mary Anne Rossing,Alicia Beeghly-Fadiel,Peter A. Fasching,Peter A. Fasching,Sandra Orsulic,Sandra Orsulic,Beth Y. Karlan,Beth Y. Karlan,Gottfried E. Konecny,David G. Huntsman,D.D. Bowtell,D.D. Bowtell,James D. Brenton,Jennifer A. Doherty,Paul D.P. Pharoah,Susan J. Ramus +292 more
TL;DR: The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovary Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival.
Journal ArticleDOI
Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
Yvette Drew,Jonathan A. Ledermann,Alison Jones,Geoffrey Hall,Gordon C Jayson,Martin Highley,Daniel Rea,R.M. Glasspool,Sarah Halford,G. Crosswell,S. Colebrook,Alan V. Boddy,Nicola J. Curtin,Elizabeth Ruth Plummer +13 more
TL;DR: AG-014699 (18mg/m2) resulted in significant PARP inhibition, was well tolerated and resulted in a clinical benefit rate (CR+PR+SD ≥ 4 months) of 32%.